Angiogenic characteristics of circulating and tumoural thrombospondin-1 in breast cancer

International Journal of Oncology

Volumn 31, Issue 5, 2007, Pages 1127-1132

  Byrne, G J ^a   Hayden, K E ^a   McDowell, G ^b   Lang, H ^a   Kirwan, C C ^a   Tetlow, L ^a   Kumar, S ^c   Bundred, N J ^a  

^a WYTHENSHAWE HOSPITAL   (United Kingdom)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Angiogenesis; Breast cancer; Tumour marker

Indexed keywords

THROMBOSPONDIN 1;

ADULT; AGED; ARTICLE; BLOOD; BREAST TUMOR; CHEMISTRY; CYTOSOL; FEMALE; HUMAN; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; VASCULARIZATION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CYTOSOL; FEMALE; HUMANS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; THROMBOSPONDIN 1;

EID: 38449086640     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Baenziger NL, Brodie GN and Majerus PW: A thrombin-sensitive protein of human platelet membranes. Proc Natl Acad Sci USA 68: 240-243, 1971.
2. Lawler J and Hynes RO: The structure of human thrombospondin, an adhesive glycoprotein with multiple calcium-binding sites and homologies with several different proteins. J Cell Biol 103: 1635-1648, 1986.
3. Dawes JCK and Gogstad L: A radioimmunoassay for thrombospondin used in a comparative study of thrombospondin, b-thromboglobulin and platelet factor-4 in healthy volunteers. Thromb Res 29: 569-581, 1983.
4. Lawler J, Weinstein R and Hynes RO: Cell attachment to thrombospondin: the role of ARG-GLY-ASP, calcium, and integrin receptors. J Cell Biol 107: 2351-2361, 1988.
5. Dreyfus M and Lahav J: The build-up of the thrombospondin extracellular matrix. An apparent dependence on synthesis and on preformed fibrillar matrix. Eur J Cell Biol 47: 275-282, 1988.
6. Asch AS, Barnwell J, Silverstein RL and Nachman RL: Isolation of the thrombospondin membrane receptor. J Clin Invest 79: 1054-1061, 1987.
7. Taraboletti G, Roberts D, Liotta LA and Giavazzi R: Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor. J Cell Biol 111: 765-772, 1990.
8. Boukerche H, Berthier-Vergnes O, Tabone E, Bailly M, Dore JF and McGregor JL: Thrombospondin modulates melanoma-platelet interactions and melanoma tumour cell growth in vivo. Br J Cancer 72: 108-116, 1995.
9. Wang TN, Qian XH, Granick MS, Solomon MP, Rothman VL and Tuszynski GP The effect of thrombospondin on oral squamous carcinoma cell invasion of collagen. Am J Surg 170: 502-505, 1995.
10. Tuszynski GP, Gasic TB, Rothman VL, Knudsen KA and Gasic GJ: Thrombospondin, a potentiator of tumor cell metastasis. Cancer Res 47: 4130-4133, 1987.
11. Incardona F, Lewalle JM, Morandi V, Lambert S, Legrand Y, Foidart JM and Legrand C: Thrombospondin modulates human breast adenocarcinoma cell adhesion to human vascular endothelial cells. Cancer Res 55: 166-173, 1995.
12. Pratt DA, Miller WR and Dawes J: Thrombospondin in malignant and non-malignant breast tissue. Eur J Cancer Clin Oncol 25: 343-350, 1989.
13. Wong SY, Purdie AT and Han P: Thrombospondin and other possible related matrix proteins in malignant and benign breast disease. An immunohistochemical study. Am J Pathol 140: 1473-1482, 1992.
14. Clezardin P, Frappart L, Clerget M, Pechoux C and Delmas PD: Expression of thrombospondin (TSP1) and its receptors (CD36 and CD51) in normal, hyperplastic, and neoplastic human breast. Cancer Res 53: 1421-1430, 1993.
15. Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA and Bouck NP: A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 87: 6624-66288, 1990.
16. Tolsma SS, Volpert OV, Good DJ, Frazier WA, Polverini PJ and Bouck N: Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol 122: 497-511, 1993.
17. BenEzra D, Griffin BW, Maftzir G and Aharonov O: Thrombospondin and in vivo angiogenesis induced by basic fibroblast growth factor or lipopolysaccharide. Invest Ophthalmol Vis Sci 34: 3601-3608, 1993.
18. Grossfeld GD, Ginsberg DA, Stein JP, Bochner BH, Esrig D, Groshen S, Dunn M, Nichols PW, Taylor CR, Skinner DG and Cote RJ: Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J Natl Cancer Inst 89: 219-227, 1997.
19. Agam G, Shohat O and Livne A: Thrombospondin plays a role in platelet-platelet recognition during release-related aggregation. Proc Soc Exp Biol Med 177: 482-486, 1984.
20. Switalska HI, Niewiarowski S, Tuszynski GP, Rucinski B, Schmaier AH, Morinelli TA and Cierniewski CS: Radioimmunoassay of human platelet thrombospondin: different patterns of thrombospondin and beta-thromboglobulin antigen secretion and clearance from the circulation. J Lab Clin Med 106: 690-700, 1985.
21. Dawes J, Pratt DA, Dewar MS and Preston FE: Do extra-platelet sources contribute to the plasma level of thrombospondin? Thromb Haemost 59: 273-276, 1988.
22. Trzeciak MC, McGregor J, Renaux JL, Ville D, Berruyer M, Dawes J and Dechavanne M: Plasma thrombospondin in patients with chronic renal failure, liver disease and splenectomy. Thromb Res 40: 121-128, 1985.
23. Hayden K, Tetlow L, Byrne G and Bundred N: Radioimmunoassay for the measurement of thrombospondin in plasma and breast cyst fluid: validation and clinical application. Ann Clin Biochem 37: 319-325, 2000.
24. Nathan FE, Hernandez E, Dunton CJ, Treat J, Switalska HI, Joseph RR and Tuszynski GP: Plasma thrombospondin levels in patients with gynecologic malignancies. Cancer 73: 2853-2858, 1994.
25. Yamashita Y, Kurohiji T, Tuszynski GP, Sakai T and Shirakusa T: Plasma thrombospondin levels in patients with colorectal carcinoma. Cancer 82: 632-638, 1998.
26. Ozatli D, Kocoglu H, Haznedaroglu IC, Kosar A, Buyukasik Y, Ozcebe O, Kirazli S and Dundar SV: Circulating thrombomodulin, thrombospondin, and fibronectin in acute myeloblastic leukemias. Haematologia (Budap) 29: 277-283, 1999.
27. 131I-labeled human growth hormone of high specific radioactivity. Biochem J 89: 114-123, 1963.
28. Chalkley H: Method for quantitation morphological analysis of tissues. J Natl Cancer Inst 4: 47-53, 1943.
29. Fidler IJ and Ellis LM: The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79: 185-188, 1994.
30. Bicknell R and Harris AL: Novel growth regulatory factors and tumour angiogenesis. Eur J Cancer 27: 781-785, 1991.
31. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31, 1995.
32. Riser BL, Varani JK and Dixit VM: Thrombospondin binding by human squamous carcinoma and melanoma cells: relationship to biological activity. Exp Cell Res 174: 319-329, 1988.
33. Qian X and Tuszynski GP: Expression of thrombospondin-1 in cancer: a role in tumor progression. Proc Soc Exp Biol Med 212: 199-207, 1996.
34. Yamashita Y, Kurohiji T, Tuszynski GP, Sakai T and Shirakusa T: Plasma thrombospondin levels in patients with colorectal carcinoma. Cancer 82: 632-638, 1998.
35. Tuszynski GP, Smith M, Rothman VL, Capuzzi DM, Joseph RR, Katz J, Besa EC, Treat J and Switalska HI: Thrombospondin levels in patients with malignancy. Thromb Haemost 67: 607-611, 1992.
36. Lane DA, Ireland H, Wolff S, Ranasinghe E and Dawes J: Detection of enhanced in vivo platelet alpha-granule release in different patient groups - comparison of beta-thromboglobulin, platelet factor 4 and thrombospondin assays. Thromb Haemost 52: 183-187, 1984.
37. Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P, Pezzella F, Viale G, Weidner N, Harris AL and Dirix LY: Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 32A: 2474-2484, 1996.
38. Weidner N, Semple JP, Welch WR and Folkman J: Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 324: 1-8, 1991.
39. Kumar S, Ghellal A, Li C, Byrne G, Haboubi N, Wang JM and Bundred N: Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res 59: 856-861, 1999.
40. Horak ER, Leek R, Klenk N, Le Jeune S, Smith K, Stuart N, Greenall M, Stepniewska K and Harris AL: Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 340: 1120-1124, 1992.
41. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S and Gasparini G: Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84: 1875-1887, 1992.
42. Bevilacqua MP: Endothelial-leukocyte adhesion molecules. Ann Rev Immunol 11: 767-804, 1993.